fashion -WSS

fashion

author：hotspot 2025-09-27 17:02:47 - browse：5339

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： App could help diagnose ear infections more accurately — and at home

leisure time

knowledge

WSS

Custom gene therapy hints at new path for rare disease treatments

Virtual Event: March of the Biosimilars

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Google and Epic fight stronger regulation of AI in health care

Neuroscience’s long legacy of racism

UnitedHealth increases loan offers after Change Healthcare outage

entertainment

fashion

hotspot

In age of alternative facts, a scholarly course on calling out crap

Creating egg and sperm cells from stem cells raises ethical issues

Novavax promises a turnaround & Lilly roils the obesity market

Medicare has a new plan to address drug shortages

The cancer drug shortage isn’t new — and neither are the solutions

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

In Memoriam: Notable people who died in 2023

FDA approves RSV monoclonal antibody for infants, toddlers

Activists slam private health insurers over coverage restrictions

Neuroscience’s long legacy of racism

focus

Group opposing PBM reform sets lobbying record

Custom gene therapy hints at new path for rare disease treatments

Health AI adoption puts security, privacy startups on investors' radar

Stop the failed accountable care organization experiment

Cosmetics set for new safety regulation. Why the industry is on board

UnitedHealth increases loan offers after Change Healthcare outage

leisure time

knowledge

hotspot

entertainment